New FDA framework tilts toward consistency over flexibility

Summary

The FDA is moving toward a more consistent approach for assessing rare disease drugs, shifting away from flexible regulatory standards. The article indicates a policy shift by FDA leadership regarding rare disease drug evaluation criteria.